Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Raphaël Toueg"'
Autor:
Adèle L’Hostis, Jean-Louis Palgen, Angélique Perrillat-Mercerot, Emmanuel Peyronnet, Evgueni Jacob, James Bosley, Michaël Duruisseaux, Raphaël Toueg, Lucile Lefèvre, Riad Kahoul, Nicoletta Ceres, Claudio Monteiro
Publikováno v:
npj Systems Biology and Applications, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Lung adenocarcinoma (LUAD) is associated with a low survival rate at advanced stages. Although the development of targeted therapies has improved outcomes in LUAD patients with identified and specific genetic alterations, such as activating
Externí odkaz:
https://doaj.org/article/3e54093f844f49948535eddc19fa9f5f
Autor:
Adèle L'Hostis, Jean-Louis Palgen, Angélique Perrillat-Mercerot, Emmanuel Peyronnet, Evgueni Jacob, James R. Bosley, Michaël Duruisseaux, Raphaël Toueg, Lucile Lefèvre, Riad Kahoul, Nicoletta Ceres, Claudio Monteiro
Lung adenocarcinoma (LUAD) is associated with a low survival rate at advanced stages. Although the development of targeted therapies has improved the survival of LUAD patients with identified and specific genetic alterations, such as mutations on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83a4196c81bb29689085789ae8f8c3a0
https://doi.org/10.21203/rs.3.rs-2405647/v1
https://doi.org/10.21203/rs.3.rs-2405647/v1
Autor:
Perrine Masson, Claire Couty, Arnaud Nativel, Evgueni Jacob, Raphaël Toueg, Michaël Duruisseaux, Adèle L'Hostis, Jean-Louis Palgen, Claudio Monteiro
Publikováno v:
Cancer Research. 83:859-859
Introduction Epidermal growth factor receptor (EGFR) mutations occur in about 40% of Asian and 13-25% of Western patients with lung adenocarcinoma (LUAD) [1,2]. EGFR tyrosine kinase inhibitors (TKIs) have been developed to target tumors with an EGFR